Before the widespread use of measles vaccine, measles was a common illness in early childhood and was associated with substantial mortality. Although surveillance systems were still in their infancy during the 1960s, .600,000 measles cases were reported annually in the Region of the Americas, reaching incidence rates .150 cases per 100,000 population [1] . Although measles vaccine was introduced during the 1960s, it was the creation of the Expanded Program on Immunization (EPI) in 1977 that marked the beginning of sustained decreases in case numbers. During 1970 During -1979 , Latin American countries reported 220,000 measles cases annually, with incidence rates of 47-116 cases/100,000 population [2] . Highest mortality rates occurred among young children; from 1971 through 1980, measlesassociated mortality was 14-55 measles-associated deaths per 100,000 infants and 8-54 deaths/100,000 children aged 1-4 years. By 1980, most countries in the region had established national immunization programs; however, the mean infant measles vaccine coverage in the region was only 42%.
EPI programs were progressively strengthened throughout the 1980s. During the decade, measles vaccination resulted in decreased disease incidence and lengthening of interepidemic intervals ( Figure 1 ). By 1990, measles vaccine coverage among infants in the Americas had reached 77%. Nevertheless, despite improvements in immunization coverage with a single measles vaccine dose, outbreaks continued to occur.
By the early 1990s, several countries pioneered a strategy recommended by the Pan American Health Organization (PAHO) to deliver measles vaccine to all children aged 9 months through 14 years in a catch-up campaign. The strategy appeared to be capable of interrupting endemic measles transmission. The first catch-up campaign in the region was launched in Cuba in 1986 [3] . In 1988, the ministers of health in the English-speaking Caribbean countries and territories declared their commitment to eliminate endemic measles by 1995. A catch-up campaign in 1991 achieved 90% measles vaccine coverage in the Caribbean [4, 5] . In December 1991, presidents of Central American countries announced the goal of eliminating measles within 6 years (by 1997) from their subregion. Catch-up campaigns were conducted throughout Central America in 1992 and 1993, reaching 89% of children. In South America, Brazil, Chile, and Peru catch-up campaigns were performed in 1992. In 1993, similar catch-up campaigns were completed in Argentina, Colombia, the Dominican Republic, and Mexico [6] . As a result, reported measles cases in the region reached a historic low in 1993 (n 5 57,400), a rate of 10 measles cases per 100,000 population. Regional coverage with the first dose of measlescontaining vaccine reached 83%.
During the 24th Pan American Sanitary Conference in 1994, ministers of health passed resolution CSP24.R16, setting a goal to eliminate measles from the Region of the Americas by 2000. The approval of the resolution was based on the impressive and rapid reduction in measles burden that had been demonstrated by countries that pioneered the use of catch-up campaigns. Subsequent resolutions passed in 1995 (Resolution CD38.R6 passed in 1995 approved a Regional Plan of Action for Measles Elimination) and 1996 (Resolution CE188.R14 passed in 1996 urged all countries to assign the necessary human and financial resources to fully implement the strategies outlined in the Regional plan) provided additional elements of the measles elimination plan.
The present article describes the measles elimination experience in the Americas, which paved the way for a global eradication goal by demonstrating the feasibility of regional measles elimination.
METHODOLOGY
Measles elimination in the Americas is defined as the interruption of endemic measles virus transmission in all countries of the Americas for a period R12 months, in the presence of high-quality surveillance.
To achieve measles elimination, PAHO recommended 3 immunization strategies: (1) 1-time mass vaccination of children and adolescents with measles-containing vaccine (ie, catch-up), (2) routine immunization of successive birth cohorts (ie, keepup), and (3) periodic mass vaccination of young children to prevent accumulation of susceptible individuals (ie, follow-up). In 2003, after the adoption of a resolution to eliminate rubella and congenital rubella syndrome (CRS) from the Americas by 2010, a fourth strategy, referred to as ''speed-up,'' called for a 1-time mass vaccination of older adolescents and adults with combined measles-rubella (MR) vaccines. In addition to vaccination strategies, PAHO emphasized the importance of sensitive, case-based measles surveillance with diagnostic laboratory capabilities. The vaccination and surveillance strategies were revised to include use of combined measles-mumps-rubella (MMR) vaccine or measles-mumps (MR) vaccine, fully integrate measles and rubella surveillance, and establish CRS surveillance (Table 1 ). [10] elimination (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) . The final phase includes the effects of rubella elimination activities, which contributed to maintaining measles elimination status.
Countries in the Americas annually report vaccination coverage with the first dose of measles-containing vaccine (MCV1) to PAHO. MCV1 is calculated for most countries by dividing the number of doses administered by the target population for vaccination (ie, administrative method). We calculated regional coverage estimates by multiplying reported coverage by target population estimates for each country. Coverage with a second dose of measles-containing vaccine (MCV2) is provided by some countries that include 2 doses in routine immunization schedules. Although PAHO recommends that immunization programs provide a second opportunity for measles vaccination, either through routine immunization services or through periodic follow-up campaigns, countries have chosen different strategies and age at which to provide a second opportunity.
PAHO recommends using standardized measles and/or rubella surveillance indicators to allow a transparent and uniform monitoring of surveillance data across countries. Depending on the moment or elimination phase, these indicators have been established and adapted over time. Since 2003, the indicators have included weekly reporting from 80% of surveillance sites, investigation within 48 h after notification and collection of an acute-phase serum specimen for 80% of suspected cases, report of laboratory results for 80% of samples within 4 days after receipt, receipt of 80% of samples in the laboratory within 5 days, and classification of 95% of nonmeasles cases on the basis of laboratory investigations.
Results

Vaccination
Routine Delivery of Measles Vaccine.
All countries and territories in the Americas have used measles vaccines since the inception of national immunization programs during the late 1970s. As part of EPI, measles vaccination was recommended at 9 months of age. In 1997, the PAHO Technical Advisory Group on Vaccine-Preventable Diseases (TAG) recommended increasing the age of routine measles vaccination to 12 months (to increase measles vaccine effectiveness). In addition, TAG recommended use of combined MR or MMR vaccines for routine infant immunization in countries with rubella and CRS control programs [11] . By 2002, a total of 40 countries and territories had changed to MMR vaccine for MCV1 and 21 countries and territories were providing a second routine dose of MMR vaccine. By 2009, all countries and territories used MMR or MR vaccine for the first routine dose, and 29 were providing MCV2.
In the early EPI period (1980-1986), regional MCV1 coverage was 42%-59% annually. During the early elimination phase (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) , MCV1 coverage had increased to 61%-83%. Since 1998, regional MCV1 coverage has been sustained at R90%. Delivery Measles Vaccine in National Campaigns. Most countries and territories in the region have provided measlescontaining vaccines in national catch-up, follow-up, and speed-up campaigns. PAHO estimates that 440 million persons received MR-containing vaccines during these campaigns [9, 12] . From 1987 through 2009, measles elimination has led to some 157 national measles vaccination campaigns in the Americas.
During 1987-1995, there were a total of 38 national catch-up campaigns for children 9 months-14 years of age. The last of these was conducted in Paraguay in 1995. A catch-up campaign conducted in Canada during 1996-1997 was not included, because it covered only 5 provinces [13] . Coverage levels achieved in the 38 national catch-up campaigns were R95% in 18 (47%), 90%-94% in 6 (16%), 80%-89% in 8 (21%), and ,80% in 6 (16%) countries and territories. Among the 39 catch-up campaigns, 23 (59%) used single-antigen measles vaccine, 1 (3%) used MR vaccine, and 14 (36%) used MMR vaccine. . Coverage was R95% for 21 (54%), 90%-94% for 7 (18%), 80%-89% for 7 (18%), and ,80% for 4 (10%). The 11 countries achieving ,90% were from the English-speaking Caribbean subregion. Among the 39 national speed-up campaigns, 25 (64%) used MR vaccine, and 14 (36%) used MMR vaccine. Speed-up and follow-up campaigns conclude with rapid coverage monitoring activities as a way to guarantee the implementation of highquality campaigns.
Bermuda and the United States did not conduct mass campaigns, because they had already achieved many years of high coverage with 2 routine doses of MMR vaccine. Several other countries have attempted to substitute MCV2 instead of followup campaigns. However, the PAHO TAG has advised that only in countries in which coverage of R95% with each of the 2 routine MMR vaccine doses is guaranteed for all municipalities can the follow-up campaigns be waived [14, 15] . Although an expected baseline for the incidence of suspected measles and/or rubella cases is used as an indicator of the intensity of measles and/or rubella surveillance, it has proven to be difficult to develop a population-based indicator for measles [16] in the last 3 years (regional reporting rate for suspected measles and/or rubella cases per 100,000 population during 2007-2009 was 6.4, 4.6, and 2.2, respectively).
Measles Epidemiology in the Americas
The impact of all the vaccination activities can be viewed broadly in the number of measles cases reported during 1980-2010 (Figure 3) . During the early days of the EPI (1980-1986), the regional annual mean number of reported measles cases was 204,498 ( Table 2 ). As regional measles vaccine coverage levels increased during 1987-1994, the regional annual mean number of measles cases decreased by some 40%, to 122,534. During 1989-1991, the countries of Central America reported persistent measles outbreaks, with disease incidence peaking in 1990 at 136 measles cases per 100,000 population. After investigations linked these outbreaks to low coverage with measles vaccine, there was a renewed effort to increase routine vaccine coverage in this subregion, and catch-up campaigns were also implemented during 1992-1993 in Central America [17] .
During Among 45 countries and territories that provided data during 1996-2002, 22 (49%) countries and territories reported no laboratory-confirmed measles cases, whereas 7 (16%) countries and territories reported .1000 cases. Details of larger measles outbreaks during this period are summarized in Table 3 .
Molecular epidemiology provides information linking epidemiologic case investigations with measles virus genotypes. Genotype D6 was considered to be endemic in the Americas, associated with 1997 outbreaks in Brazil and subsequent outbreaks in Argentina, Bolivia, Haiti, and the Dominican Republic [18] . Absence of D6 virus despite identification of genotypes from other regions supports elimination of the D6 genotype from the Americas [19] . During 2001 During -2002 , an outbreak of a previously unknown genotype, D9, was first identified in Venezuela and, later, in Colombia. Subsequent investigations identified D9 genotype measles in Indonesia, suggesting that D9 viruses may have been imported into Venezuela from an unidentified index case [20] . 
DISCUSSION
Eight years passed from the time Resolution CSP24.R16 was adopted, calling for measles elimination, to the declaration that endemic measles virus transmission was interrupted in the Region of the Americas. Elimination was ultimately achieved through the commitment of an entire region to reach a common goal, the subsequent and full implementation of the PAHOrecommended vaccination and surveillance strategies by the countries, and the dedication of the health care workers in the Americas.
It is estimated that the full cost of a measles mass campaign id US $0.50-0.75 per child. When using the MR vaccine, the cost per child is estimated at US $1.00-1.20. The vaccination strategy http://jid.oxfordjournals.org/ toward achieving measles elimination in Latin American and Caribbean countries cost an estimated US$ 244 million over the entire period, incremental to the cost of vaccination before the elimination program. From 2000 through 2020, the current program will have prevented the occurrence of 3.2 million cases of measles and 16,000 deaths. Thus, the vaccination strategy prevents a single case of measles at the cost of US$71.75 and prevents a death due to measles at the cost of US$15,000 [21] . The case-fatality rate depends on a well-functioning treatment program for measles cases. The vaccination strategy saves a total of US$208 million in treatments costs resulting from reduced incidence of measles.
Several factors created the environment necessary for a measles elimination goal. Political commitment at all levels was cultivated, and proactive support was provided for the elimination initiative. The countries of the region prepared plans of action that outlined resource allocation and human resource support. Designs of effective campaigns were clearly defined, and most of the countries that had conducted mass vaccination campaigns had also established surveillance systems with laboratory support. Finally, several national and multinational initiatives to eliminate measles were underway that were having a major impact on the incidence of the disease.
Measles elimination was achieved and maintained by the countries of the Americas by building on lessons learned from .30 years of experience in implementing disease elimination strategies. These included: (1) monitoring coverage at the district or municipal level, (2) building consensus among various stakeholders, (3) resource mobilization, (4) alliances with scientific associations, (5) relationships with the private sector, (6) social mobilization around the regional elimination goal, (7) effective communication strategies, (8) integrated measles and rubella surveillance, and (9) mass vaccination with combined MR vaccines. To build consensus, PAHO provided evidence of the technical feasibility of elimination. Alliances with scientific associations created advocacy for measles elimination goals and provided positive media exposure for partner organizations. PAHO encouraged private sector involvement to improve completion of immunization schedules and detection of suspected cases by surveillance systems. PAHO successfully engaged ministries of health and local health care workers in social mobilization around the elimination goal. Local participation in communication strategies for immunization campaigns fostered a sense of ownership. When countries achieved elimination, there was a collective feeling of success.
Several challenges for reaching elimination were confronted by the countries of the Americas. Campaigns, although effective, are complex. Adequate organization and close supervision are required to ensure that groups of the target population are not missed, in which virus transmission could be maintained. The purpose of PAHO's recommendation for countries to conduct high-quality follow-up campaigns was to prevent the Outbreaks are just one of the many challenges confronted during the postelimination era and are reminders that, until global measles eradication is achieved, countries in the Americas are at risk of importations of measles virus. Countries must therefore maintain high-quality elimination strategies, strengthen sensitive surveillance to rapidly detect and respond to importations and isolated cases, improve coordination with the private sector, and strengthen coordination with dengue surveillance. Ongoing surveillance challenges include the need to obtain appropriate specimens from case patients and contacts and to rapidly transport these to the laboratory. When the incidence of disease has been dramatically reduced, sporadic cases pose a diagnostic challenge because of the potential for false-positive or false-negative laboratory results. With virus elimination as a target, laboratories must establish proper virus containment procedures.
The decision by the countries of the Americas to eliminate rubella and CRS served as a catalyst to strengthen measles elimination efforts. Mass vaccination of adults and adolescents with combined MR vaccines for rubella elimination boosted measles immunity in the population to prevent the reestablishment of endemic measles virus transmission. In addition, rubella elimination has encouraged countries to switch from single antigen measles vaccine to routine vaccination of infants with MMR vaccine and to maintain very high coverage levels. Integrating measles and rubella surveillance capitalized on existing surveillance infrastructure to improve case detection and classification without increasing costs. Network laboratories conduct measles and rubella serologic examination on all serum samples from suspected case patients. Urine or pharyngeal specimens collected from suspected case patients provide a specimen bank for virus identification and sequencing. Finally, introducing rubella elimination and its integration with measles elimination led to renewed enthusiasm of health care workers at all levels and greater support from PAHO strategic partners.
The achievement of measles elimination in the Region of the Americas effectively harnessed the trust of the population in immunization and lead to sustained demand for vaccination services for the child and family. The success of the initiative also exerted a pull effect, which has catalyzed the addition of new vaccines into routine programs and has strengthened primary health care in the Americas by basing strategies on the principal of equity and striving to deliver vaccination services to all communities, including high-risk areas where vulnerable populations are found.
Considering that a safe and affordable vaccine is available, along with the knowledge and experience on how to use it to achieve elimination, it is imperative that determined measles eradication efforts are made.
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